A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma
Stopped No activity was observed. BRAFi-naïve participants should have received triple combination treatment (including MEK inhibitor). Continuation was not justified.
Conditions
- V600-mutated BRAF Unresectable Melanoma
- V600-mutated BRAF Metastatic Melanoma
- Stage III or Stage IV Metastatic Melanoma That Has Not Been Previously Treated With a Selective BRAF Inhibitor
Interventions
- DRUG: PLX3397
- DRUG: vemurafenib
Sponsor
Daiichi Sankyo
Collaborators